25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AMLX (Amylyx) Stock Analysis
Buy, Hold or Sell?

Let's analyze Amylyx together

I guess you are interested in Amylyx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Amylyx’s Financial Insights
  • 📈 Technical Analysis (TA) – Amylyx’s Price Targets

I'm going to help you getting a better view of Amylyx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Amylyx (30 sec.)










1.2. What can you expect buying and holding a share of Amylyx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.26
Expected worth in 1 year
$0.88
How sure are you?
38.9%

+ What do you gain per year?

Total Gains per Share
$-1.38
Return On Investment
-21.0%

For what price can you sell your share?

Current Price per Share
$6.57
Expected price per share
$4.8 - $11.82
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Amylyx (5 min.)




Live pricePrice per Share (EOD)
$6.57
Intrinsic Value Per Share
$-8.92 - $-10.20
Total Value Per Share
$-6.66 - $-7.94

2.2. Growth of Amylyx (5 min.)




Is Amylyx growing?

Current yearPrevious yearGrowGrow %
How rich?$201.4m$390.6m-$184.7m-89.7%

How much money is Amylyx making?

Current yearPrevious yearGrowGrow %
Making money-$54.7m-$17.7m-$36.9m-67.5%
Net Profit Margin-1,181.1%-21.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Amylyx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#250 / 884

Most Revenue
#878 / 884

Most Profit
#799 / 884

Most Efficient
#718 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Amylyx?

Welcome investor! Amylyx's management wants to use your money to grow the business. In return you get a share of Amylyx.

First you should know what it really means to hold a share of Amylyx. And how you can make/lose money.

Speculation

The Price per Share of Amylyx is $6.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amylyx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amylyx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.26. Based on the TTM, the Book Value Change Per Share is $-0.35 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amylyx.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.40-6.1%-0.61-9.3%-0.20-3.0%-0.41-6.2%-0.36-5.5%-0.36-5.5%
Usd Book Value Change Per Share0.416.3%-0.35-5.3%-0.08-1.2%-0.04-0.6%0.131.9%0.131.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.416.3%-0.35-5.3%-0.08-1.2%-0.04-0.6%0.131.9%0.131.9%
Usd Price Per Share3.54-3.12-14.36-15.30-10.91-10.91-
Price to Earnings Ratio-2.20--1.50-27.53-40.07-26.38-26.38-
Price-to-Total Gains Ratio8.61--2.31-48.24-27.55-25.65-25.65-
Price to Book Ratio1.57-1.43-3.17-5.15-3.70-3.70-
Price-to-Total Gains Ratio8.61--2.31-48.24-27.55-25.65-25.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.57
Number of shares152
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.350.13
Usd Total Gains Per Share-0.350.13
Gains per Quarter (152 shares)-52.4419.08
Gains per Year (152 shares)-209.7776.32
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-210-22007666
20-420-4300153142
30-629-6400229218
40-839-8500305294
50-1049-10600382370
60-1259-12700458446
70-1468-14800534522
80-1678-16900611598
90-1888-19000687674
100-2098-21100763750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%4.08.00.033.3%4.014.00.022.2%4.014.00.022.2%4.014.00.022.2%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%7.09.02.038.9%7.09.02.038.9%7.09.02.038.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%7.09.02.038.9%7.09.02.038.9%7.09.02.038.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Amylyx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.411-0.345+184%-0.079+119%-0.037+109%0.126+228%0.126+228%
Book Value Per Share--2.2602.310-2%4.382-48%3.194-29%1.983+14%1.983+14%
Current Ratio--12.0546.983+73%6.582+83%6.961+73%6.077+98%6.077+98%
Debt To Asset Ratio--0.0830.166-50%0.159-48%0.160-48%1.312-94%1.312-94%
Debt To Equity Ratio--0.0910.204-55%0.192-53%0.193-53%1.819-95%1.819-95%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--501368508.160465745788.960+8%1571197753.440-68%1597415724.533-69%1579704990.831-68%1579704990.831-68%
Eps---0.403-0.614+52%-0.199-51%-0.410+2%-0.364-10%-0.364-10%
Ev To Ebitda Ratio---3.329-2.806-16%57.578-106%-17.901+438%-17.075+413%-17.075+413%
Free Cash Flow Per Share---0.447-0.581+30%0.043-1132%-0.316-29%-0.289-35%-0.289-35%
Free Cash Flow To Equity Per Share--0.290-0.396+237%0.051+471%0.152+91%0.247+17%0.247+17%
Gross Profit Margin--1.0001.0000%0.498+101%0.863+16%0.909+10%0.909+10%
Intrinsic Value_10Y_max---10.196----------
Intrinsic Value_10Y_min---8.924----------
Intrinsic Value_1Y_max---1.232----------
Intrinsic Value_1Y_min---1.210----------
Intrinsic Value_3Y_max---3.541----------
Intrinsic Value_3Y_min---3.384----------
Intrinsic Value_5Y_max---5.657----------
Intrinsic Value_5Y_min---5.265----------
Market Cap585657053.280+46%315559508.160277674538.960+14%1280066253.440-75%1363858891.200-77%972876104.489-68%972876104.489-68%
Net Profit Margin----11.8110%-0.2170%-17.1550%-17.3110%-17.3110%
Operating Margin---4.629-100%-0.2430%-11.9180%-13.7770%-13.7770%
Operating Ratio---17.817-100%1.243-100%19.984-100%22.455-100%22.455-100%
Pb Ratio2.908+46%1.5671.433+9%3.171-51%5.153-70%3.699-58%3.699-58%
Pe Ratio-4.078-86%-2.197-1.504-32%27.528-108%40.073-105%26.383-108%26.383-108%
Price Per Share6.570+46%3.5403.115+14%14.360-75%15.300-77%10.914-68%10.914-68%
Price To Free Cash Flow Ratio-3.676-86%-1.980-1.445-27%-26.278+1227%-22.796+1051%-15.585+687%-15.585+687%
Price To Total Gains Ratio15.979+46%8.610-2.307+127%48.236-82%27.547-69%25.653-66%25.653-66%
Quick Ratio--19.44411.097+75%8.756+122%10.391+87%8.921+118%8.921+118%
Return On Assets---0.163-0.217+32%-0.045-72%-0.141-14%-0.306+87%-0.306+87%
Return On Equity---0.178-0.264+48%-0.062-65%-0.173-3%-0.506+184%-0.506+184%
Total Gains Per Share--0.411-0.345+184%-0.079+119%-0.037+109%0.126+228%0.126+228%
Usd Book Value--201417000.000205923500.000-2%390658250.000-48%284699916.667-29%176774000.000+14%176774000.000+14%
Usd Book Value Change Per Share--0.411-0.345+184%-0.079+119%-0.037+109%0.126+228%0.126+228%
Usd Book Value Per Share--2.2602.310-2%4.382-48%3.194-29%1.983+14%1.983+14%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--501368508.160465745788.960+8%1571197753.440-68%1597415724.533-69%1579704990.831-68%1579704990.831-68%
Usd Eps---0.403-0.614+52%-0.199-51%-0.410+2%-0.364-10%-0.364-10%
Usd Free Cash Flow---39835000.000-51770750.000+30%3861000.000-1132%-28198500.000-29%-25752722.222-35%-25752722.222-35%
Usd Free Cash Flow Per Share---0.447-0.581+30%0.043-1132%-0.316-29%-0.289-35%-0.289-35%
Usd Free Cash Flow To Equity Per Share--0.290-0.396+237%0.051+471%0.152+91%0.247+17%0.247+17%
Usd Market Cap585657053.280+46%315559508.160277674538.960+14%1280066253.440-75%1363858891.200-77%972876104.489-68%972876104.489-68%
Usd Price Per Share6.570+46%3.5403.115+14%14.360-75%15.300-77%10.914-68%10.914-68%
Usd Profit---35907000.000-54714250.000+52%-17773750.000-51%-36575500.000+2%-32404277.778-10%-32404277.778-10%
Usd Revenue----318000.0000%99500250.000-100%40865583.333-100%27279000.000-100%27279000.000-100%
Usd Total Gains Per Share--0.411-0.345+184%-0.079+119%-0.037+109%0.126+228%0.126+228%
 EOD+6 -2MRQTTM+27 -7YOY+15 -203Y+19 -165Y+21 -1410Y+21 -14

3.3 Fundamental Score

Let's check the fundamental score of Amylyx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.078
Price to Book Ratio (EOD)Between0-12.908
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than119.444
Current Ratio (MRQ)Greater than112.054
Debt to Asset Ratio (MRQ)Less than10.083
Debt to Equity Ratio (MRQ)Less than10.091
Return on Equity (MRQ)Greater than0.15-0.178
Return on Assets (MRQ)Greater than0.05-0.163
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.732
Ma 20Greater thanMa 505.690
Ma 50Greater thanMa 1005.265
Ma 100Greater thanMa 2004.421
OpenGreater thanClose6.380
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-06-28 22:36:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Amylyx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,181.1%+1,181.1%
TTM-1,181.1%YOY-21.7%-1,159.4%
TTM-1,181.1%5Y-1,731.1%+550.0%
5Y-1,731.1%10Y-1,731.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM-1,181.1%-141.4%-1,039.7%
YOY-21.7%-186.1%+164.4%
3Y-1,715.5%-248.3%-1,467.2%
5Y-1,731.1%-338.6%-1,392.5%
10Y-1,731.1%-488.9%-1,242.2%
4.3.1.2. Return on Assets

Shows how efficient Amylyx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • -16.3% Return on Assets means that Amylyx generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is -16.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-21.7%+5.3%
TTM-21.7%YOY-4.5%-17.1%
TTM-21.7%5Y-30.6%+8.9%
5Y-30.6%10Y-30.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-11.5%-4.8%
TTM-21.7%-11.6%-10.1%
YOY-4.5%-11.4%+6.9%
3Y-14.1%-11.8%-2.3%
5Y-30.6%-12.1%-18.5%
10Y-30.6%-13.8%-16.8%
4.3.1.3. Return on Equity

Shows how efficient Amylyx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • -17.8% Return on Equity means Amylyx generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is -17.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.8%TTM-26.4%+8.5%
TTM-26.4%YOY-6.2%-20.2%
TTM-26.4%5Y-50.6%+24.2%
5Y-50.6%10Y-50.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.8%-13.6%-4.2%
TTM-26.4%-14.9%-11.5%
YOY-6.2%-14.4%+8.2%
3Y-17.3%-17.0%-0.3%
5Y-50.6%-17.9%-32.7%
10Y-50.6%-20.1%-30.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Amylyx Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Amylyx is operating .

  • Measures how much profit Amylyx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM462.9%-462.9%
TTM462.9%YOY-24.3%+487.2%
TTM462.9%5Y-1,377.7%+1,840.6%
5Y-1,377.7%10Y-1,377.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM462.9%-250.3%+713.2%
YOY-24.3%-205.1%+180.8%
3Y-1,191.8%-220.2%-971.6%
5Y-1,377.7%-342.6%-1,035.1%
10Y-1,377.7%-475.5%-902.2%
4.3.2.2. Operating Ratio

Measures how efficient Amylyx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM17.817-17.817
TTM17.817YOY1.243+16.574
TTM17.8175Y22.455-4.637
5Y22.45510Y22.4550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM17.8172.704+15.113
YOY1.2433.063-1.820
3Y19.9843.576+16.408
5Y22.4554.713+17.742
10Y22.4556.512+15.943
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Amylyx Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Amylyx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.05 means the company has $12.05 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 12.054. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.983. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.054TTM6.983+5.070
TTM6.983YOY6.582+0.401
TTM6.9835Y6.077+0.906
5Y6.07710Y6.0770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.0543.661+8.393
TTM6.9833.786+3.197
YOY6.5824.121+2.461
3Y6.9614.680+2.281
5Y6.0775.765+0.312
10Y6.0776.150-0.073
4.4.3.2. Quick Ratio

Measures if Amylyx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Quick Ratio of 19.44 means the company can pay off $19.44 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 19.444. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.097. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ19.444TTM11.097+8.347
TTM11.097YOY8.756+2.340
TTM11.0975Y8.921+2.175
5Y8.92110Y8.9210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.4442.826+16.618
TTM11.0973.128+7.969
YOY8.7563.782+4.974
3Y10.3914.304+6.087
5Y8.9215.703+3.218
10Y8.9216.454+2.467
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Amylyx Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Amylyx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amylyx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Amylyx assets are financed with 8.3% credit (debt) and the remaining percentage (100% - 8.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.083. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.166. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.083TTM0.166-0.083
TTM0.166YOY0.159+0.007
TTM0.1665Y1.312-1.146
5Y1.31210Y1.3120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0830.324-0.241
TTM0.1660.347-0.181
YOY0.1590.327-0.168
3Y0.1600.339-0.179
5Y1.3120.349+0.963
10Y1.3120.382+0.930
4.5.4.2. Debt to Equity Ratio

Measures if Amylyx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.1% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.091. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.204. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.091TTM0.204-0.113
TTM0.204YOY0.192+0.011
TTM0.2045Y1.819-1.616
5Y1.81910Y1.8190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0910.383-0.292
TTM0.2040.436-0.232
YOY0.1920.410-0.218
3Y0.1930.446-0.253
5Y1.8190.460+1.359
10Y1.8190.509+1.310
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amylyx generates.

  • Above 15 is considered overpriced but always compare Amylyx to the Biotechnology industry mean.
  • A PE ratio of -2.20 means the investor is paying $-2.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is -4.078. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.197. Based on the earnings, the company is expensive. -2
  • The TTM is -1.504. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.078MRQ-2.197-1.881
MRQ-2.197TTM-1.504-0.693
TTM-1.504YOY27.528-29.032
TTM-1.5045Y26.383-27.887
5Y26.38310Y26.3830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.078-2.197-1.881
MRQ-2.197-2.027-0.170
TTM-1.504-2.527+1.023
YOY27.528-3.733+31.261
3Y40.073-3.717+43.790
5Y26.383-6.036+32.419
10Y26.383-6.649+33.032
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is -3.676. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.980. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.445. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.676MRQ-1.980-1.695
MRQ-1.980TTM-1.445-0.535
TTM-1.445YOY-26.278+24.833
TTM-1.4455Y-15.585+14.140
5Y-15.58510Y-15.5850.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.676-3.007-0.669
MRQ-1.980-2.704+0.724
TTM-1.445-3.627+2.182
YOY-26.278-4.334-21.944
3Y-22.796-5.070-17.726
5Y-15.585-8.532-7.053
10Y-15.585-9.305-6.280
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Amylyx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.57 means the investor is paying $1.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 2.908. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.567. Based on the equity, the company is underpriced. +1
  • The TTM is 1.433. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.908MRQ1.567+1.341
MRQ1.567TTM1.433+0.134
TTM1.433YOY3.171-1.738
TTM1.4335Y3.699-2.266
5Y3.69910Y3.6990.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9081.921+0.987
MRQ1.5671.843-0.276
TTM1.4332.113-0.680
YOY3.1712.467+0.704
3Y5.1532.541+2.612
5Y3.6993.666+0.033
10Y3.6994.311-0.612
4.6.2. Total Gains per Share

2.4. Latest News of Amylyx Pharmaceuticals Inc

Does Amylyx Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Amylyx Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-11
16:08
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amylyx Pharmaceuticals Inc.

4.8.1. Institutions holding Amylyx Pharmaceuticals Inc

Institutions are holding 85.88% of the shares of Amylyx Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Perceptive Advisors LLC8.83360.98217874348110000016.2377
2025-03-31TCG Crossover Management, LLC6.66792.87025943812130000027.9942
2025-03-31Adage Capital Partners Gp LLC6.39170.0374569760556976050
2025-03-31Vanguard Group Inc4.6180.00034116512142402352.8887
2025-03-31Millennium Management LLC3.45730.005830818532487617418.6244
2025-03-31Nantahala Capital Management, LLC3.29190.412829344051482252102.0727
2025-03-31Citadel Advisors Llc3.09370.0019275777678707239.9386
2025-03-31Aberdeen Group PLC2.72640.0168243035870755341.0698
2025-03-31Saturn V Capital Management LLC2.7224.334724264361537363172.9175
2025-03-31683 Capital Management LLC2.70510.5888241140048140024.943
2025-03-31BlackRock Inc2.67820.000223874091084754.7599
2025-03-31Almitas Capital LLC2.38122.49312122597902274.4395
2025-03-31Goldman Sachs Group Inc2.2470.001220029611430657.6921
2025-03-31Great Point Partners LLC2.03273.3976181199618119960
2025-03-31Boxer Capital Management, LLC1.96321.8633175000000
2025-03-31Woodline Partners LP1.80550.0371160944716094470
2025-03-31ADAR1 Capital Management LLC1.65090.9671147158714715870
2025-03-31Susquehanna International Group, LLP1.65010.0009147092560254369.3869
2025-03-31Connor Clark & Lunn Inv Mgmt Ltd1.34580.01851199691-63662-5.0391
2025-03-31FMR Inc1.29910.0003115798842663258.3344
Total 63.561318.030156659106+23205195+41.0%

4.9.2. Funds holding Amylyx Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Total Stock Mkt Idx Inv2.57710.0007229724100
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.28590.00541146267106910.9415
2025-04-30Fidelity Select Biotechnology1.28460.15114507500
2025-05-31abrdn Healthcare Investors0.73020.3677650947-1080875-62.4126
2025-04-30Fidelity Extended Market Index0.42830.0054381812-3649-0.9467
2025-05-31iShares Biotechnology ETF0.40730.037536308800
2025-02-28Biotech Growth Ord0.39040.350534800000
2025-03-31Vanguard Strategic Small-Cap Equity Inv0.3890.075434673514559872.3875
2025-05-31Schwab US Small-Cap ETF™0.36470.0101325076-851-0.2611
2025-05-31abrdn Life Sciences Investors0.31230.3582278361-483879-63.4812
2025-05-31iShares U.S. Small-Cap Eq Fac ETF0.26350.071123489100
2025-05-31Vanguard Health Care ETF0.22210.0058198018110985.9373
2025-05-31Xtrackers S&P 500 Swap ETF 1C0.20540.009318305500
2025-03-31Federated Hermes MDT Small Cap Growth IS0.17660.124715741200
2025-03-31Federated Hermes MDT SCG Institutional0.17660.124815741200
2025-03-31Bridgeway Ultra-Small Company Market0.16430.529514650000
2025-04-30Fidelity Total Market Index0.14810.000713200400
2025-05-31iShares Micro-Cap ETF0.14310.084712751700
2025-03-31Extended Equity Market Fund K0.13370.00321192003650.3071
2025-05-31Avantis US Small Cap Equity ETF0.1320.04011176812640.2248
Total 9.93522.35488856292-1401238-15.8%

5.3. Insider Transactions

Insiders are holding 12.466% of the shares of Amylyx Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-03-31Camille L BedrosianSELL124253.47
2025-03-31James M FratesSELL108963.47
2025-03-31Joshua B CohenSELL214903.47
2025-03-20Bernhardt G ZeiherBUY100003.7
2025-02-24Gina MazzarielloSELL41693.15
2025-02-03Gina MazzarielloSELL36783.49
2025-02-03Joshua B CohenSELL118513.47
2025-01-06Justin B KleeSELL74714.04
2024-09-30Camille L BedrosianSELL114423.2
2024-09-30Justin B KleeSELL185893.2
2024-09-12James M FratesBUY400002.53
2024-09-03George M Milne JrBUY1000002.2
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets219,676
Total Liabilities18,259
Total Stockholder Equity201,417
 As reported
Total Liabilities 18,259
Total Stockholder Equity+ 201,417
Total Assets = 219,676

Assets

Total Assets219,676
Total Current Assets216,144
Long-term Assets3,532
Total Current Assets
Cash And Cash Equivalents 59,764
Short-term Investments 144,304
Net Receivables 300
Other Current Assets 11,776
Total Current Assets  (as reported)216,144
Total Current Assets  (calculated)216,144
+/-0
Long-term Assets
Property Plant Equipment 2,072
Long-term Assets Other 1,460
Long-term Assets  (as reported)3,532
Long-term Assets  (calculated)3,532
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,932
Long-term Liabilities327
Total Stockholder Equity201,417
Total Current Liabilities
Short-term Debt 1,055
Accounts payable 4,810
Other Current Liabilities 12,067
Total Current Liabilities  (as reported)17,932
Total Current Liabilities  (calculated)17,932
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt327
Long-term Liabilities  (as reported)327
Long-term Liabilities  (calculated)327
+/-0
Total Stockholder Equity
Common Stock9
Retained Earnings -642,599
Other Stockholders Equity 844,007
Total Stockholder Equity (as reported)201,417
Total Stockholder Equity (calculated)201,417
+/-0
Other
Capital Stock9
Cash and Short Term Investments 204,068
Common Stock Shares Outstanding 85,697
Liabilities and Stockholders Equity 219,676
Net Debt -58,382
Net Invested Capital 201,417
Net Working Capital 198,212
Property Plant and Equipment Gross 2,072
Short Long Term Debt Total 1,382



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
14,104
0
0
130,460
105,614
274,438
225,240
181,443
391,453
407,958
453,588
466,584
517,454
417,457
332,162
250,713
193,634
219,676
219,676193,634250,713332,162417,457517,454466,584453,588407,958391,453181,443225,240274,438105,614130,4600014,104
   > Total Current Assets 
13,639
12,877
0
129,942
101,510
265,488
216,139
171,629
382,133
389,053
427,394
434,110
464,666
410,534
326,722
245,263
189,432
216,144
216,144189,432245,263326,722410,534464,666434,110427,394389,053382,133171,629216,139265,488101,510129,942012,87713,639
       Cash And Cash Equivalents 
12,877
-12,877
0
76,677
50,191
110,403
67,440
107,734
62,526
114,563
247,760
135,258
170,201
170,552
74,999
71,839
77,391
59,764
59,76477,39171,83974,999170,552170,201135,258247,760114,56362,526107,73467,440110,40350,19176,6770-12,87712,877
       Short-term Investments 
0
25,754
0
49,025
45,927
144,802
139,241
54,859
284,419
231,111
109,516
219,787
201,161
202,741
234,813
162,556
99,110
144,304
144,30499,110162,556234,813202,741201,161219,787109,516231,111284,41954,859139,241144,80245,92749,025025,7540
       Net Receivables 
0
0
0
0
0
0
0
137
15,306
17,555
33,473
29,353
40,050
20,351
4,091
1,731
447
300
3004471,7314,09120,35140,05029,35333,47317,55515,3061370000000
       Other Current Assets 
762
0
0
4,240
8,833
20,566
18,916
8,906
10,113
12,749
11,787
17,338
14,931
16,890
12,819
9,137
12,484
11,776
11,77612,4849,13712,81916,89014,93117,33811,78712,74910,1138,90618,91620,5668,8334,24000762
   > Long-term Assets 
465
-12,877
0
518
4,104
8,950
9,101
9,814
9,320
18,905
26,194
32,474
52,788
6,923
5,440
5,450
4,202
3,532
3,5324,2025,4505,4406,92352,78832,47426,19418,9059,3209,8149,1018,9504,1045180-12,877465
       Property Plant Equipment 
151
0
0
329
474
8,075
8,226
8,069
8,135
7,647
7,280
6,950
6,411
5,711
4,242
3,527
2,732
2,072
2,0722,7323,5274,2425,7116,4116,9507,2807,6478,1358,0698,2268,07547432900151
       Long-term Assets Other 
125
-12,877
0
189
3,441
456
456
1,026
466
466
466
476
45,658
493
479
1,923
1,470
1,460
1,4601,4701,92347949345,6584764664664661,0264564563,4411890-12,877125
> Total Liabilities 
80,829
0
0
254,530
256,782
33,492
32,451
37,415
50,846
55,310
67,223
48,184
84,022
93,021
70,853
54,510
28,869
18,259
18,25928,86954,51070,85393,02184,02248,18467,22355,31050,84637,41532,45133,492256,782254,5300080,829
   > Total Current Liabilities 
7,326
0
0
15,146
17,396
27,706
27,164
32,647
46,609
49,523
64,082
45,617
82,042
91,639
70,081
53,915
28,406
17,932
17,93228,40653,91570,08191,63982,04245,61764,08249,52346,60932,64727,16427,70617,39615,146007,326
       Short-term Debt 
0
0
0
263
0
2,810
3,574
3,980
2,040
4,186
2,146
4,402
4,514
4,624
2,369
1,972
1,518
1,055
1,0551,5181,9722,3694,6244,5144,4022,1464,1862,0403,9803,5742,8100263000
       Short Long Term Debt 
0
0
0
263
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000263000
       Accounts payable 
3,613
0
0
3,026
4,372
10,045
8,117
7,052
6,257
10,770
24,695
6,371
22,061
21,453
4,955
1,487
2,939
4,810
4,8102,9391,4874,95521,45322,0616,37124,69510,7706,2577,0528,11710,0454,3723,026003,613
       Other Current Liabilities 
3,713
0
0
11,857
13,024
14,851
15,473
21,615
38,312
36,660
37,241
34,844
55,467
65,562
62,757
50,456
23,949
12,067
12,06723,94950,45662,75765,56255,46734,84437,24136,66038,31221,61515,47314,85113,02411,857003,713
   > Long-term Liabilities 
73,503
0
0
239,384
239,386
5,786
5,287
4,768
4,237
5,787
3,141
2,567
1,980
1,382
772
595
463
327
3274635957721,3821,9802,5673,1415,7874,2374,7685,2875,786239,386239,3840073,503
       Long term Debt 
1,425
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,425
       Capital Lease Obligations Min Short Term Debt
0
0
0
-263
0
4,381
3,500
2,778
4,237
1,601
3,141
366
-277
-930
772
595
463
327
327463595772-930-2773663,1411,6014,2372,7783,5004,3810-263000
       Other Liabilities 
16
0
0
0
35
0
7,074
0
0
0
0
0
0
0
0
0
0
0
000000000007,07403500016
       Long-term Liabilities Other 
0
0
0
0
0
5,786
5,287
4,768
4,237
3,694
0
0
0
0
0
0
0
0
000000003,6944,2374,7685,2875,78600000
> Total Stockholder Equity
-66,725
5,337
0
-124,070
-151,168
240,946
192,789
144,028
340,607
352,648
386,365
418,400
433,432
324,436
261,309
196,203
164,765
201,417
201,417164,765196,203261,309324,436433,432418,400386,365352,648340,607144,028192,789240,946-151,168-124,07005,337-66,725
   Common Stock
1
0
0
1
1
6
6
6
7
7
7
7
7
7
7
7
7
9
977777777766611001
   Retained Earnings -642,599-606,692-569,146-496,442-423,742-304,949-309,680-330,573-352,647-354,220-311,516-257,760-203,693-155,845-127,50100-67,914
   Capital Surplus 
0
0
0
0
0
444,784
450,739
456,263
694,906
705,263
0
0
0
0
0
0
0
0
00000000705,263694,906456,263450,739444,78400000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
1,188
0
0
-235,920
4,667
444,784
450,739
456,263
694,906
705,263
717,003
728,224
738,177
748,248
757,841
764,701
771,542
844,007
844,007771,542764,701757,841748,248738,177728,224717,003705,263694,906456,263450,739444,7844,667-235,920001,188



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue87,371
Cost of Revenue-42,156
Gross Profit-37,26245,215
 
Operating Income (+$)
Gross Profit-37,262
Operating Expense-359,946
Operating Income-314,731-397,208
 
Operating Expense (+$)
Research Development104,084
Selling General Administrative114,331
Selling And Marketing Expenses0
Operating Expense359,946218,415
 
Net Interest Income (+$)
Interest Income13,809
Interest Expense-0
Other Finance Cost-0
Net Interest Income13,809
 
Pretax Income (+$)
Operating Income-314,731
Net Interest Income13,809
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-302,136-327,326
EBIT - interestExpense = -302,136
-302,136
-301,743
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-302,136-302,136
Earnings Before Interest and Taxes (EBITDA)-301,232
 
After tax Income (+$)
Income Before Tax-302,136
Tax Provision--393
Net Income From Continuing Ops-301,743-301,743
Net Income-301,743
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses402,102
Total Other Income/Expenses Net12,595-13,809
 

Technical Analysis of Amylyx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amylyx. The general trend of Amylyx is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amylyx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Amylyx Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amylyx Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 6.7 < 7.27 < 11.82.

The bearish price targets are: 6.08 > 5.85 > 4.8.

Know someone who trades $AMLX? Share this with them.👇

Amylyx Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amylyx Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amylyx Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amylyx Pharmaceuticals Inc. The current macd is 0.3873193.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amylyx price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Amylyx. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Amylyx price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Amylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAmylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amylyx Pharmaceuticals Inc. The current adx is 30.28.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Amylyx shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Amylyx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amylyx Pharmaceuticals Inc. The current sar is 4.98255049.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Amylyx Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amylyx Pharmaceuticals Inc. The current rsi is 67.73. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Amylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAmylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amylyx Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amylyx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Amylyx Pharmaceuticals Inc Daily Stochastic Oscillator ChartAmylyx Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amylyx Pharmaceuticals Inc. The current cci is 124.31.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Amylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAmylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amylyx Pharmaceuticals Inc. The current cmo is 42.29.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Amylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAmylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amylyx Pharmaceuticals Inc. The current willr is -13.86861314.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Amylyx Pharmaceuticals Inc Daily Williams %R ChartAmylyx Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amylyx Pharmaceuticals Inc. The current atr is 0.43930073.

Amylyx Pharmaceuticals Inc Daily Average True Range (ATR) ChartAmylyx Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amylyx Pharmaceuticals Inc. The current obv is -48,729,841.

Amylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAmylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amylyx Pharmaceuticals Inc. The current mfi is 41.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAmylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amylyx Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-21BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Amylyx Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.732
Ma 20Greater thanMa 505.690
Ma 50Greater thanMa 1005.265
Ma 100Greater thanMa 2004.421
OpenGreater thanClose6.380
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Amylyx with someone you think should read this too:
  • Are you bullish or bearish on Amylyx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Amylyx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Amylyx Pharmaceuticals Inc.

Receive notifications about Amylyx Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.